Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-04-22

Clinical Trial Update: A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder [Phase 3]

View source ↗

Summary

Phase 3 study of CYB003, a deuterated psilocin analog, in adults with major depressive disorder is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CYB003 (deuterated psilocin analog)

Snippet

Sponsor: Cybin IRL Limited | Conditions: Major Depressive Disorder (MDD), Depression in Adults | Phase 3 | Status: RECRUITING